Global New Drug Development Company
Enzychem Lifesciences Corporation is a Global New Drug Development Company that was founded on the most advanced life sciences and technologies of medicinal chemistry in July 1999.
With its Global New Drug R&D center in Seoul and two GMP manufacturing plants in Seoul Korea, it has since been developing and producing APIs and functional health foods, and developing global new drugs as the leader of the field.
Enzychem Lifesciences is an innovative enterprise, marketing APIs both domestically and overseas. It has been developing global new drugs to treat chemotherapy-induced neutropenia, chemo-radiation therapy-induced oral mucositis,asthma, psoriasis, rheumatoid arthritis, atopic dermatitis, sepsis, acute radiation syndrome and other autoimmune disorders, utilizing EC-18 (PLAG, a substance naturally duplicated from deer antlers).Enzychem also owns dozens of intellectual properties with regard to the processes and uses of EC-18, and the processes of first generic pharmaceutical ingredients.